A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-10

AUTHORS

Karen A. Gelmon, Karl Belanger, Denis Soulieres, Carolyn Britten, Stephen Chia, Danielle Charpentier, Kim Chi, Jean Powers, Wendy Walsh, Lesley Seymour

ABSTRACT

BACKGROUND: T900607 is a novel tubulin active agent which disrupts microtubule polymerization by a unique mechanism of action. This phase I trial was conducted to determine the maximum tolerated dose, recommended phase II dose, pharmacokinetic properties and toxicities of this agent. PATIENTS AND METHODS: Patients with advanced and/or metastatic solid malignancies were enrolled, for an open dose escalation of T900607 administered intravenously over 30 minutes every 21-days. RESULTS: Thirty patients were enrolled on 7 dose levels ranging from 15 to 270 mg/m(2). No DLTs were seen until 270 mg/m(2), the sixth dose level, with 1 patient experiencing Grade 3 thrombocytopenia, 1 grade 4 troponin increase and 1 grade 5 myocardial infarction in an expanded cohort of 6 patients. The dose was decreased to 180 mg/m(2) with increased cardiac monitoring and at this dose 3/4 patients experienced cardiac toxicity. Further animal cardiotoxicity studies failed to reveal any cardiac effects and the study was reopened at 130 mg/m(2); of 6 enrolled patients, 1 had grade 3 drug related lethargy considered to be a DLT and this dose was considered the RP2D. No objective responses were seen but stable disease was reported in 7/20. Pharmacokinetic analysis showed that AUC and C(max) increased with dose with considerable intrapatient variability, a short half life of < 1 hour, and no apparent dose dependency clearance. CONCLUSIONS: The recommended phase II dose for T900607 is 130 mg/m(2) given as an intravenous infusion over 60 minutes on a 21-day cycle. Cardiac toxicity was seen with this schedule. More... »

PAGES

445-453

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-005-2904-2

DOI

http://dx.doi.org/10.1007/s10637-005-2904-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1042796117

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16133796


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fatigue", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nausea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thrombocytopenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vomiting", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Vancouver Cancer Centre, V5Z 4E6, Vancouver, BC, Canada", 
            "British Columbia Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, V5Z 4E6, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gelmon", 
        "givenName": "Karen A.", 
        "id": "sg:person.01173252503.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173252503.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al", 
          "id": "https://www.grid.ac/institutes/grid.410559.c", 
          "name": [
            "CHUM\u2014Pavillon Notre Dame, Montreal, Quebec"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Belanger", 
        "givenName": "Karl", 
        "id": "sg:person.01024266460.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024266460.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al", 
          "id": "https://www.grid.ac/institutes/grid.410559.c", 
          "name": [
            "CHUM\u2014Pavillon Notre Dame, Montreal, Quebec"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soulieres", 
        "givenName": "Denis", 
        "id": "sg:person.0720307321.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720307321.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Vancouver Cancer Centre, V5Z 4E6, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Britten", 
        "givenName": "Carolyn", 
        "id": "sg:person.0703012037.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703012037.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Vancouver Cancer Centre, V5Z 4E6, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chia", 
        "givenName": "Stephen", 
        "id": "sg:person.0743651364.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743651364.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al", 
          "id": "https://www.grid.ac/institutes/grid.410559.c", 
          "name": [
            "CHUM\u2014Pavillon Notre Dame, Montreal, Quebec"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Charpentier", 
        "givenName": "Danielle", 
        "id": "sg:person.01215343535.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215343535.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Vancouver Cancer Centre, V5Z 4E6, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "Kim", 
        "id": "sg:person.01142252161.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "NCIC Clinical Trials Group, K7L 3N6, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Powers", 
        "givenName": "Jean", 
        "id": "sg:person.0764776730.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764776730.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "NCIC Clinical Trials Group, K7L 3N6, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Walsh", 
        "givenName": "Wendy", 
        "id": "sg:person.01033112130.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033112130.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "NCIC Clinical Trials Group, K7L 3N6, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seymour", 
        "givenName": "Lesley", 
        "id": "sg:person.01327242410.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327242410.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejme020049", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008062671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.16.1295", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008088052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.286.19.2405", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014904485"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000109491.66226.26", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018354952"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/268739a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023741078", 
          "https://doi.org/10.1038/268739a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci119642", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035491262"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199610313351802", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037752660"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(01)01388-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039641479"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/1568011023354290", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069191902"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.21.3.621", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071514762"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.3.1061", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074262194"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074484574", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-10", 
    "datePublishedReg": "2005-10-01", 
    "description": "BACKGROUND: T900607 is a novel tubulin active agent which disrupts microtubule polymerization by a unique mechanism of action. This phase I trial was conducted to determine the maximum tolerated dose, recommended phase II dose, pharmacokinetic properties and toxicities of this agent.\nPATIENTS AND METHODS: Patients with advanced and/or metastatic solid malignancies were enrolled, for an open dose escalation of T900607 administered intravenously over 30 minutes every 21-days.\nRESULTS: Thirty patients were enrolled on 7 dose levels ranging from 15 to 270 mg/m(2). No DLTs were seen until 270 mg/m(2), the sixth dose level, with 1 patient experiencing Grade 3 thrombocytopenia, 1 grade 4 troponin increase and 1 grade 5 myocardial infarction in an expanded cohort of 6 patients. The dose was decreased to 180 mg/m(2) with increased cardiac monitoring and at this dose 3/4 patients experienced cardiac toxicity. Further animal cardiotoxicity studies failed to reveal any cardiac effects and the study was reopened at 130 mg/m(2); of 6 enrolled patients, 1 had grade 3 drug related lethargy considered to be a DLT and this dose was considered the RP2D. No objective responses were seen but stable disease was reported in 7/20. Pharmacokinetic analysis showed that AUC and C(max) increased with dose with considerable intrapatient variability, a short half life of < 1 hour, and no apparent dose dependency clearance.\nCONCLUSIONS: The recommended phase II dose for T900607 is 130 mg/m(2) given as an intravenous infusion over 60 minutes on a 21-day cycle. Cardiac toxicity was seen with this schedule.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-005-2904-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "name": "A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC\u2013CTG) IND 130", 
    "pagination": "445-453", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "cbdb243b2f4c4ef3151ac6826a6735537db1e905f790cc3df399be189bdb02c0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16133796"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-005-2904-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1042796117"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-005-2904-2", 
      "https://app.dimensions.ai/details/publication/pub.1042796117"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000359_0000000359/records_29182_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-005-2904-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-2904-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-2904-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-2904-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-2904-2'


 

This table displays all metadata directly associated to this object as RDF triples.

234 TRIPLES      21 PREDICATES      56 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-005-2904-2 schema:about N00d20b95b3b645369dd1af76508be20c
2 N1b7dbe0dda7f40c6b4d84703d16efde9
3 N26c5a04eb582441386d5fa7dd2e48bed
4 N2d4850b53db44fe2a6143c1ad9dd605a
5 N35551c78f26741bf85bd0da551add7e6
6 N3ac59b9a202d42c2b5b2b99810e9dd9f
7 N4338fb9b51b94937994d606d1a63831a
8 N64b88436fd254dcea31884218c64da11
9 N7d72491dc3b64996a0968dbf8ba77272
10 N8b460059776d418f8e250b1521c781da
11 Naead1d9c5a3146199349aa96533676b3
12 Nc16a0bc6fa5a462d8b906c3bb4f6ad42
13 Ncc8093a8c87f43c096a8624a1d35785f
14 Ne01925a82abf41c5b7b37bb0a2eeeee7
15 anzsrc-for:11
16 anzsrc-for:1115
17 schema:author N19eaadf1eb0644aca1702b7257f0cfd3
18 schema:citation sg:pub.10.1038/268739a0
19 https://app.dimensions.ai/details/publication/pub.1074484574
20 https://doi.org/10.1001/jama.286.19.2405
21 https://doi.org/10.1016/s0735-1097(01)01388-2
22 https://doi.org/10.1056/nejm199610313351802
23 https://doi.org/10.1056/nejme020049
24 https://doi.org/10.1093/jnci/92.16.1295
25 https://doi.org/10.1093/jnci/92.3.205
26 https://doi.org/10.1161/01.cir.0000109491.66226.26
27 https://doi.org/10.1172/jci119642
28 https://doi.org/10.1200/jco.1999.17.3.1061
29 https://doi.org/10.2174/1568011023354290
30 https://doi.org/10.3892/ijo.21.3.621
31 schema:datePublished 2005-10
32 schema:datePublishedReg 2005-10-01
33 schema:description BACKGROUND: T900607 is a novel tubulin active agent which disrupts microtubule polymerization by a unique mechanism of action. This phase I trial was conducted to determine the maximum tolerated dose, recommended phase II dose, pharmacokinetic properties and toxicities of this agent. PATIENTS AND METHODS: Patients with advanced and/or metastatic solid malignancies were enrolled, for an open dose escalation of T900607 administered intravenously over 30 minutes every 21-days. RESULTS: Thirty patients were enrolled on 7 dose levels ranging from 15 to 270 mg/m(2). No DLTs were seen until 270 mg/m(2), the sixth dose level, with 1 patient experiencing Grade 3 thrombocytopenia, 1 grade 4 troponin increase and 1 grade 5 myocardial infarction in an expanded cohort of 6 patients. The dose was decreased to 180 mg/m(2) with increased cardiac monitoring and at this dose 3/4 patients experienced cardiac toxicity. Further animal cardiotoxicity studies failed to reveal any cardiac effects and the study was reopened at 130 mg/m(2); of 6 enrolled patients, 1 had grade 3 drug related lethargy considered to be a DLT and this dose was considered the RP2D. No objective responses were seen but stable disease was reported in 7/20. Pharmacokinetic analysis showed that AUC and C(max) increased with dose with considerable intrapatient variability, a short half life of < 1 hour, and no apparent dose dependency clearance. CONCLUSIONS: The recommended phase II dose for T900607 is 130 mg/m(2) given as an intravenous infusion over 60 minutes on a 21-day cycle. Cardiac toxicity was seen with this schedule.
34 schema:genre research_article
35 schema:inLanguage en
36 schema:isAccessibleForFree false
37 schema:isPartOf Naf77388ccd0844dbbcc861b1ffb8e1ac
38 Nfb835067aae94f98ae5b76d88648f3c4
39 sg:journal.1094201
40 schema:name A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130
41 schema:pagination 445-453
42 schema:productId N2c8d5bdcf9b0401893bfda5587c3bdfd
43 N4f1f1bcef75d4a8289207c923ba06016
44 N90e79b76edd84244a295dd6bf6fb1f77
45 Nb1aa0442051f45b78aab42186c7239fd
46 Nf0d302b3c6804780a6aa02946cca80dd
47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042796117
48 https://doi.org/10.1007/s10637-005-2904-2
49 schema:sdDatePublished 2019-04-11T11:50
50 schema:sdLicense https://scigraph.springernature.com/explorer/license/
51 schema:sdPublisher Na7554fd4b57944559f603cb7c91e1269
52 schema:url http://link.springer.com/10.1007%2Fs10637-005-2904-2
53 sgo:license sg:explorer/license/
54 sgo:sdDataset articles
55 rdf:type schema:ScholarlyArticle
56 N00d20b95b3b645369dd1af76508be20c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Thrombocytopenia
58 rdf:type schema:DefinedTerm
59 N0e9b7ddbb63b4343bd8c1bb70f780aba rdf:first sg:person.0764776730.50
60 rdf:rest N81d33a197df7489c9b6004e7fb332863
61 N185d5f09ae074caf9031f35693a2da7d rdf:first sg:person.0703012037.15
62 rdf:rest N6c7803fe24c744498a4ed87555bb69af
63 N19eaadf1eb0644aca1702b7257f0cfd3 rdf:first sg:person.01173252503.80
64 rdf:rest N93485844059e4d479259c180e72daf55
65 N1b7dbe0dda7f40c6b4d84703d16efde9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Humans
67 rdf:type schema:DefinedTerm
68 N26c5a04eb582441386d5fa7dd2e48bed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Male
70 rdf:type schema:DefinedTerm
71 N2c8d5bdcf9b0401893bfda5587c3bdfd schema:name dimensions_id
72 schema:value pub.1042796117
73 rdf:type schema:PropertyValue
74 N2d4850b53db44fe2a6143c1ad9dd605a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Neoplasms
76 rdf:type schema:DefinedTerm
77 N35551c78f26741bf85bd0da551add7e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Heart
79 rdf:type schema:DefinedTerm
80 N3ac59b9a202d42c2b5b2b99810e9dd9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Aged
82 rdf:type schema:DefinedTerm
83 N4338fb9b51b94937994d606d1a63831a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Female
85 rdf:type schema:DefinedTerm
86 N4f1f1bcef75d4a8289207c923ba06016 schema:name doi
87 schema:value 10.1007/s10637-005-2904-2
88 rdf:type schema:PropertyValue
89 N64b88436fd254dcea31884218c64da11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Fatigue
91 rdf:type schema:DefinedTerm
92 N6c7803fe24c744498a4ed87555bb69af rdf:first sg:person.0743651364.39
93 rdf:rest N706ceba245b14d57987d2c0b7500b31c
94 N706ceba245b14d57987d2c0b7500b31c rdf:first sg:person.01215343535.53
95 rdf:rest N7e00d4e1e6cc477999f29c2337c39878
96 N7d72491dc3b64996a0968dbf8ba77272 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Vomiting
98 rdf:type schema:DefinedTerm
99 N7e00d4e1e6cc477999f29c2337c39878 rdf:first sg:person.01142252161.65
100 rdf:rest N0e9b7ddbb63b4343bd8c1bb70f780aba
101 N81d33a197df7489c9b6004e7fb332863 rdf:first sg:person.01033112130.98
102 rdf:rest Nf26c4b9b87e74316a21e0d9f430f88be
103 N8b460059776d418f8e250b1521c781da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Antineoplastic Agents
105 rdf:type schema:DefinedTerm
106 N90e79b76edd84244a295dd6bf6fb1f77 schema:name readcube_id
107 schema:value cbdb243b2f4c4ef3151ac6826a6735537db1e905f790cc3df399be189bdb02c0
108 rdf:type schema:PropertyValue
109 N93485844059e4d479259c180e72daf55 rdf:first sg:person.01024266460.81
110 rdf:rest Nf29df18de78b4704bce9d859f3711d70
111 Na7554fd4b57944559f603cb7c91e1269 schema:name Springer Nature - SN SciGraph project
112 rdf:type schema:Organization
113 Naead1d9c5a3146199349aa96533676b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Middle Aged
115 rdf:type schema:DefinedTerm
116 Naf77388ccd0844dbbcc861b1ffb8e1ac schema:volumeNumber 23
117 rdf:type schema:PublicationVolume
118 Nb1aa0442051f45b78aab42186c7239fd schema:name pubmed_id
119 schema:value 16133796
120 rdf:type schema:PropertyValue
121 Nc16a0bc6fa5a462d8b906c3bb4f6ad42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Sulfonamides
123 rdf:type schema:DefinedTerm
124 Ncc8093a8c87f43c096a8624a1d35785f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Nausea
126 rdf:type schema:DefinedTerm
127 Ne01925a82abf41c5b7b37bb0a2eeeee7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Adult
129 rdf:type schema:DefinedTerm
130 Nf0d302b3c6804780a6aa02946cca80dd schema:name nlm_unique_id
131 schema:value 8309330
132 rdf:type schema:PropertyValue
133 Nf26c4b9b87e74316a21e0d9f430f88be rdf:first sg:person.01327242410.25
134 rdf:rest rdf:nil
135 Nf29df18de78b4704bce9d859f3711d70 rdf:first sg:person.0720307321.27
136 rdf:rest N185d5f09ae074caf9031f35693a2da7d
137 Nfb835067aae94f98ae5b76d88648f3c4 schema:issueNumber 5
138 rdf:type schema:PublicationIssue
139 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
140 schema:name Medical and Health Sciences
141 rdf:type schema:DefinedTerm
142 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
143 schema:name Pharmacology and Pharmaceutical Sciences
144 rdf:type schema:DefinedTerm
145 sg:journal.1094201 schema:issn 0167-6997
146 1573-0646
147 schema:name Investigational New Drugs
148 rdf:type schema:Periodical
149 sg:person.01024266460.81 schema:affiliation https://www.grid.ac/institutes/grid.410559.c
150 schema:familyName Belanger
151 schema:givenName Karl
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024266460.81
153 rdf:type schema:Person
154 sg:person.01033112130.98 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
155 schema:familyName Walsh
156 schema:givenName Wendy
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033112130.98
158 rdf:type schema:Person
159 sg:person.01142252161.65 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
160 schema:familyName Chi
161 schema:givenName Kim
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65
163 rdf:type schema:Person
164 sg:person.01173252503.80 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
165 schema:familyName Gelmon
166 schema:givenName Karen A.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173252503.80
168 rdf:type schema:Person
169 sg:person.01215343535.53 schema:affiliation https://www.grid.ac/institutes/grid.410559.c
170 schema:familyName Charpentier
171 schema:givenName Danielle
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215343535.53
173 rdf:type schema:Person
174 sg:person.01327242410.25 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
175 schema:familyName Seymour
176 schema:givenName Lesley
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327242410.25
178 rdf:type schema:Person
179 sg:person.0703012037.15 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
180 schema:familyName Britten
181 schema:givenName Carolyn
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703012037.15
183 rdf:type schema:Person
184 sg:person.0720307321.27 schema:affiliation https://www.grid.ac/institutes/grid.410559.c
185 schema:familyName Soulieres
186 schema:givenName Denis
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720307321.27
188 rdf:type schema:Person
189 sg:person.0743651364.39 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
190 schema:familyName Chia
191 schema:givenName Stephen
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743651364.39
193 rdf:type schema:Person
194 sg:person.0764776730.50 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
195 schema:familyName Powers
196 schema:givenName Jean
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764776730.50
198 rdf:type schema:Person
199 sg:pub.10.1038/268739a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023741078
200 https://doi.org/10.1038/268739a0
201 rdf:type schema:CreativeWork
202 https://app.dimensions.ai/details/publication/pub.1074484574 schema:CreativeWork
203 https://doi.org/10.1001/jama.286.19.2405 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014904485
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/s0735-1097(01)01388-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039641479
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1056/nejm199610313351802 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037752660
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1056/nejme020049 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008062671
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1093/jnci/92.16.1295 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008088052
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1161/01.cir.0000109491.66226.26 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018354952
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1172/jci119642 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035491262
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1200/jco.1999.17.3.1061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074262194
220 rdf:type schema:CreativeWork
221 https://doi.org/10.2174/1568011023354290 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069191902
222 rdf:type schema:CreativeWork
223 https://doi.org/10.3892/ijo.21.3.621 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071514762
224 rdf:type schema:CreativeWork
225 https://www.grid.ac/institutes/grid.248762.d schema:alternateName BC Cancer Agency
226 schema:name British Columbia Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, V5Z 4E6, Vancouver, British Columbia, Canada
227 British Columbia Cancer Agency, Vancouver Cancer Centre, V5Z 4E6, Vancouver, BC, Canada
228 rdf:type schema:Organization
229 https://www.grid.ac/institutes/grid.410356.5 schema:alternateName Queen's University
230 schema:name NCIC Clinical Trials Group, K7L 3N6, Kingston, ON, Canada
231 rdf:type schema:Organization
232 https://www.grid.ac/institutes/grid.410559.c schema:alternateName Centre Hospitalier de l’Université de Montréal
233 schema:name CHUM—Pavillon Notre Dame, Montreal, Quebec
234 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...